Skip to main content
padlock icon - secure page this page is secure

Prospective evaluation of 68Ga‐DOTATATE PET/CT in limited disease neuroendocrine tumours and/or elevated serum neuroendocrine biomarkers

Buy Article:

$52.00 + tax (Refund Policy)

The 68Ga‐labelled somatostatin analogues (68Ga‐DOTA‐SSAs) is becoming popular as an important diagnostic tool in neuroendocrine tumours as evidenced by a growing number of reports detailing institutional experience with various DOTA peptides. However, only few prospective studies have compared 68Ga‐DOTA‐SSAs and somatostatin receptor scintigraphy (SRS) in gastroenteropancreatic neuroendocrine tumours (GEP‐NETs) and pulmonary neuroendocrine tumours.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: biomarker; gallium radiopharmaceuticals; neuroendocrine tumour; positron emission tomography; somatostatin

Document Type: Research Article

Publication date: August 1, 2018

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more